Invitrogen Obtains Rights to Orchid s SNP-Scoring Technology | GenomeWeb

NEW YORK, Nov. 28 – Invitrogen has acquired the exclusive rights to develop and market genotyping products utilizing Orchid’s SNP-scoring primer extension technology in a 96-well format, the companies said Wednesday.

Under the terms of the deal, Invitrogen of San Diego will pay Orchid of Princeton, NJ, a royalty on kit sales. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.